Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Cutis ; 66(4): 263-7, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11109148

ABSTRACT

Dermatofibrosarcoma protuberans (DFSP) is an uncommon tumor with its onset typically in the second to fifth decades of life. It most commonly presents on the trunk, and recent cytogenetic studies suggest a neural origin. A case presentation and review of the recent literature on the diagnosis, differential diagnosis, and treatment of DFSP is presented.


Subject(s)
Dermatofibrosarcoma/diagnosis , Skin Neoplasms/diagnosis , Adult , Dermatofibrosarcoma/pathology , Dermatofibrosarcoma/surgery , Diagnosis, Differential , Female , Groin/pathology , Groin/surgery , Humans , Mohs Surgery , Skin Neoplasms/pathology , Skin Neoplasms/surgery
3.
Blood ; 78(6): 1503-15, 1991 Sep 15.
Article in English | MEDLINE | ID: mdl-1715792

ABSTRACT

Monoclonal antibodies (MoAbs) specific for autoantibody associated cross-reactive idiotypes (CRIs) frequently recognize the Igs of neoplastic B cells in patients with chronic lymphocytic leukemia (CLL) and/or Waldenstrom's macroglobulinemia. Very little is known regarding the normal B cells expressing CRIs (CRI-positive B cells). Using a variety of MoAbs against CRIs we investigated the distribution and topographic localization of CRI-positive B cells in normal adult human lymphoid tissues. We found that CRI-positive B cells represent a significant B-cell subpopulation expressing surface IgM (greater than 90%), IgG (approximately 5%), or IgA (approximately 2%). CRI-positive B cells are homogeneously distributed throughout all lymphoid tissues, accounting for 10% to 15% of all B lymphocytes, with the exception of the thymus, in which they represent the predominant B cell population. Immunophenotypic studies showed (1) that a small subpopulation (3.7% +/- 0.8%) of CRI-positive B cells are activated in vivo, based on CD25 and CD38 antigen expression; and (2) that approximately 50% of CRI-positive B cells express the 67-Kd pan-T-lymphocyte CD5 antigen, suggesting that the CRI-positive B-cell subset and the recently described CD5-positive B-cell subset are closely related. This hypothesis is supported by the fact that CRI-positive B cells produce oligo or polyreactive Igs, which are a characteristic feature of CD5-positive B cells, and also by the fact that both B-cell subpopulations appear to use similar and restricted Ig VH gene family members.


Subject(s)
Antigens, CD/analysis , Autoantibodies/immunology , B-Lymphocytes/immunology , Cross Reactions/immunology , Immunoglobulin Idiotypes/immunology , Antibodies, Monoclonal/immunology , CD5 Antigens , Gene Expression Regulation/immunology , Humans , Immunoglobulin A/analysis , Immunoglobulin G/analysis , Immunoglobulin Heavy Chains/genetics , Immunoglobulin M/analysis , Lymphocyte Activation/immunology
4.
Am J Pathol ; 138(3): 591-9, 1991 Mar.
Article in English | MEDLINE | ID: mdl-1900388

ABSTRACT

The authors investigated the structural organization of the bcl-1 locus, a putative oncogene associated with reciprocal chromosomal translocation t(11;14), by Southern blot hybridization analysis and its frequency, distribution, and prognostic significance in a panel of 156 clinically and pathologically well-defined B-cell chronic lymphocytic leukemias (CLLs) and non-Hodgkin's lymphomas (NHLs). The authors detected bcl-1 rearrangements in only 2 of 42 CLLs and 4 of 114 NHLs, specifically 3 of 29 diffuse small lymphocytic and 1 of 10 diffuse small cleaved cell and none of 5 diffuse intermediate lymphocytic, 13 follicular predominantly small cleaved, 17 follicular mixed small cleaved and large cell, 4 diffuse mixed small and large cell, 26 diffuse large cell, and 10 diffuse small noncleaved cell lymphomas. None of seven cases of Rai stage III or IV CLL or seven diffuse large cell lymphomas occurring as Richter's syndrome exhibited bcl-1 rearrangements. In conclusion, the bcl-1 locus rearranges in only about 4% of B-cell CLLs and NHLs, is predominantly rearranged in low-grade B-cell neoplasms, and does not appear to be preferentially associated with those occasional CLLs and low-grade NHLs displaying clinical aggressiveness, advanced clinical stage, or large cell transformation (Richter's syndrome). Therefore the demonstration of bcl-1 rearrangement does not appear to have clinically useful prognostic significance.


Subject(s)
Gene Rearrangement , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Lymphoma, Non-Hodgkin/genetics , Proto-Oncogene Proteins/genetics , Blotting, Southern , Chromosome Mapping , Humans , Immunoglobulin Heavy Chains/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Lymphoma, Non-Hodgkin/pathology , Neoplasm Staging , Translocation, Genetic
5.
Acta Neuropathol ; 80(2): 198-203, 1990.
Article in English | MEDLINE | ID: mdl-2167605

ABSTRACT

Two patients with lymphoproliferative disorders developed peripheral neuropathy and neoplastic lymphocytic nerve infiltrates. One of these patients, with B cell small lymphocytic lymphoma, presented with a chronic axonal neuropathy. CD22+, CD5- cells were identified in the epineurium. The other patient with chronic lymphocytic leukemia of 3 years duration developed a mixed axonal and demyelinating neuropathy. CD22+ and CD5+ cells were observed in the endoneurium. While the cause of the neuropathy in these two cases is unknown, intraneural or systemic autoantibody production may have led to the development of disease.


Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Peripheral Nervous System Diseases/pathology , Spinal Nerves/pathology , Sural Nerve/pathology , Aged , Antigens, CD/analysis , B-Lymphocytes/immunology , Female , HLA-DR Antigens/analysis , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/physiopathology , Male , Peripheral Nervous System Diseases/etiology , Receptors, Antigen, B-Cell/analysis , Sural Nerve/immunology
6.
Cancer ; 63(3): 438-9, 1989 Feb 01.
Article in English | MEDLINE | ID: mdl-2912522

ABSTRACT

High-dose megestrol acetate, a synthetic progestin, has been advocated recently in treating patients with metastatic breast carcinoma; no significant increase in adverse effects has been reported. This report describes a patient with jaundice and intrahepatic cholestasis after high-dose megestrol acetate therapy. This cholestatic lesion may have a pathogenesis similar to that observed with estrogens and oral contraceptives.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Breast Neoplasms/drug therapy , Cholestasis, Intrahepatic/chemically induced , Jaundice/chemically induced , Megestrol/analogs & derivatives , Aged , Bilirubin/blood , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Female , Fluorouracil/administration & dosage , Humans , Mastectomy, Radical , Megestrol/administration & dosage , Megestrol/adverse effects , Megestrol Acetate , Methotrexate/administration & dosage , Prednisone/administration & dosage , Vincristine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...